Eli Lilly and Chinese partner Novast have started on a new plant in China to manufacture generic versions of Lilly drugs, a bit of good news on a day when manufacturing issues had otherwise cast a shadow over the Indianapolis-based drugmaker.
Regeneron is starting work on a new manufacturing plant in Limerick, Ireland, that it expects to manufacture drugs that are currently in its pipeline. But already the drugmaker is talking about an expansion and building a fill-and-finish plant nearby, at least according to Ireland's minister of finance.
Germany's Fresenius Kabi has a grant from a state government in Australia and plans to build a new manufacturing plant there.
Another piece of U.S. pharma real estate has been sold. JPMorgan has bought AstraZeneca's research campus in Delaware for $44 million, according to the Philadelphia Business Journal.
Generic drug maker Mylan turned itself into one of the largest makers of sterile injectable drugs last year with its $1.75 billion acquisition of Agila Specialties. Today the drugmaker pointed to one reason to take on all of that production capacity. Its earnings got a big boost from injectable products, in part because of drug shortages.
GlaxoSmithKline is investing £350 million in a new plant in Ulverston, U.K., that will generate 500 new jobs, increase drug capacity and potentially draw on wind power to lower its environmental impact. But what about the football fields?
Employees at GlaxoSmithKline's antibiotics manufacturing plant in Ulverston, U.K., each received a carbon monoxide alarm to celebrate nearly three and a half years of injury-free work.
Shire has garnered FDA approval to make its orphan drug Vpriv at a plant in Lexington, MA. That means it now has approval at two plants in the U.S. to manufacture the treatment for type 1 Gaucher disease.
Hikma has said revenues in its generic drug division last year were dragged down by remediation costs at a New Jersey plant that the FDA cited in 2012. Even so, the generics unit will be the star of its financial report next month, driven by sales of doxycycline, a drug that was on the FDA shortage list until recently.
Development officials in Ireland are excited about the spin-off benefits of getting a Regeneron plant in Limerick. The drugmaker is excited about having a new manufacturing facility that will produce the Irish tax benefits that are all the vogue in pharma these days.